Pavla Kadlecová

1.0k total citations
28 papers, 576 citations indexed

About

Pavla Kadlecová is a scholar working on Epidemiology, Cardiology and Cardiovascular Medicine and Neurology. According to data from OpenAlex, Pavla Kadlecová has authored 28 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 10 papers in Cardiology and Cardiovascular Medicine and 6 papers in Neurology. Recurrent topics in Pavla Kadlecová's work include Acute Ischemic Stroke Management (12 papers), Cardiac electrophysiology and arrhythmias (7 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). Pavla Kadlecová is often cited by papers focused on Acute Ischemic Stroke Management (12 papers), Cardiac electrophysiology and arrhythmias (7 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). Pavla Kadlecová collaborates with scholars based in Czechia, Croatia and United States. Pavla Kadlecová's co-authors include Robert Mikulík, Nancy L. Pedersen, Ross Andel, Janika Kõrv, Aleksandras Vilionskis, Viktor Švigelj, Günther Krumpl, M Brozman, László Csiba and Vida Demarin and has published in prestigious journals such as Blood, Stroke and The Journals of Gerontology Series A.

In The Last Decade

Pavla Kadlecová

26 papers receiving 562 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pavla Kadlecová Czechia 13 251 135 111 101 100 28 576
David Orion Israel 14 456 1.8× 18 0.1× 140 1.3× 111 1.1× 264 2.6× 48 754
Rohan Pathansali United Kingdom 10 164 0.7× 9 0.1× 198 1.8× 152 1.5× 111 1.1× 12 544
Sylvia Metz‐Schimmerl Austria 9 95 0.4× 21 0.2× 78 0.7× 47 0.5× 23 0.2× 14 577
Judith Frayne Australia 11 321 1.3× 9 0.1× 127 1.1× 60 0.6× 97 1.0× 18 510
Robert G. Hart United States 13 276 1.1× 15 0.1× 517 4.7× 84 0.8× 447 4.5× 22 1.2k
Ewa Straburzyńska‐Migaj Poland 18 121 0.5× 77 0.6× 562 5.1× 8 0.1× 13 0.1× 103 948
Mojca Stegnar Slovenia 8 124 0.5× 16 0.1× 180 1.6× 113 1.1× 14 0.1× 16 516
Prahlad Ho Australia 13 58 0.2× 37 0.3× 161 1.5× 188 1.9× 37 0.4× 53 464
Jun Young Chang South Korea 16 350 1.4× 3 0.0× 85 0.8× 80 0.8× 237 2.4× 79 804
G. Y. H. Lip United Kingdom 13 97 0.4× 10 0.1× 502 4.5× 104 1.0× 17 0.2× 34 805

Countries citing papers authored by Pavla Kadlecová

Since Specialization
Citations

This map shows the geographic impact of Pavla Kadlecová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavla Kadlecová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavla Kadlecová more than expected).

Fields of papers citing papers by Pavla Kadlecová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavla Kadlecová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavla Kadlecová. The network helps show where Pavla Kadlecová may publish in the future.

Co-authorship network of co-authors of Pavla Kadlecová

This figure shows the co-authorship network connecting the top 25 collaborators of Pavla Kadlecová. A scholar is included among the top collaborators of Pavla Kadlecová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavla Kadlecová. Pavla Kadlecová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krumpl, Günther, et al.. (2020). Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults. BMC Pharmacology and Toxicology. 21(1). 82–82. 7 indexed citations
2.
Krumpl, Günther, et al.. (2020). Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol. Cureus. 12(12). e12217–e12217. 1 indexed citations
3.
Gisslinger, Heinz, Veronika Buxhofer‐Ausch, Josef Thaler, et al.. (2018). Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results. Blood. 132(Supplement 1). 3030–3030. 12 indexed citations
4.
Tsivgoulis, Georgios, Aristeidis H. Katsanos, Pavla Kadlecová, et al.. (2017). Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry. Journal of Neurology. 264(5). 912–920. 22 indexed citations
5.
Krumpl, Günther, et al.. (2017). Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. European Journal of Clinical Pharmacology. 73(4). 417–428. 26 indexed citations
6.
Krumpl, Günther, et al.. (2017). Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites. Journal of Cardiovascular Pharmacology. 70(1). 42–51. 11 indexed citations
7.
Krumpl, Günther, et al.. (2016). Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. European Journal of Pharmaceutical Sciences. 92. 64–73. 12 indexed citations
8.
Šedová, Petra, Robert D. Brown, Miroslav Zvolský, et al.. (2016). Incidence of Hospitalized Stroke in the Czech Republic: The National Registry of Hospitalized Patients. Journal of Stroke and Cerebrovascular Diseases. 26(5). 979–986. 18 indexed citations
9.
Tichá, Veronika, et al.. (2016). Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study. Clinical Drug Investigation. 37(2). 175–186. 15 indexed citations
10.
Hakl, Roman, et al.. (2016). Hereditary angio-oedema with C1 inhibitor deficiency: Characteristics and diagnostic delay of Czech patients from one centre. Allergologia et Immunopathologia. 44(3). 241–245. 2 indexed citations
11.
Volný, Ondřej, Petra Cimflová, Pavla Kadlecová, et al.. (2016). Single-Phase Versus Multiphase CT Angiography in Middle Cerebral Artery Clot Detection—Benefits for Less Experienced Radiologists and Neurologists. Journal of Stroke and Cerebrovascular Diseases. 26(1). 19–24. 22 indexed citations
12.
Kadlecová, Pavla, Ross Andel, & Robert Mikulík. (2015). Alcohol Consumption at Midlife and Risk of Stroke During 43 Years of Follow-Up Cohort and Twin Analyses. Journal of Vascular Surgery. 62(1). 266–266. 1 indexed citations
13.
Tsivgoulis, Georgios, Pavla Kadlecová, Adam Kobayashi, et al.. (2015). Safety of Statin Pretreatment in Intravenous Thrombolysis for Acute Ischemic Stroke. Stroke. 46(9). 2681–2684. 24 indexed citations
14.
Šedová, Petra, Robert D. Brown, Miroslav Zvolský, et al.. (2015). Validation of Stroke Diagnosis in the National Registry of Hospitalized Patients in the Czech Republic. Journal of Stroke and Cerebrovascular Diseases. 24(9). 2032–2038. 27 indexed citations
15.
Andel, Ross, et al.. (2015). Midlife Alcohol Consumption and Risk of Dementia Over 43 Years of Follow-Up: A Population-Based Study From the Swedish Twin Registry. The Journals of Gerontology Series A. 70(10). 1248–1254. 50 indexed citations
16.
Gisslinger, Heinz, Oleh Zagrijtschuk, Veronika Buxhofer‐Ausch, et al.. (2015). Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 126(15). 1762–1769. 130 indexed citations
17.
Haršány, Michal, Pavla Kadlecová, Viktor Švigelj, et al.. (2014). Factors Influencing Door-to-Imaging Time: Analysis of the Safe Implementation of Treatments in Stroke–EAST Registry. Journal of Stroke and Cerebrovascular Diseases. 23(8). 2122–2129. 11 indexed citations
18.
19.
Novotná, J, Pavla Kadlecová, Anna Członkowska, et al.. (2014). Hyperdense Cerebral Artery Computed Tomography Sign Is Associated with Stroke Severity Rather than Stroke Subtype. Journal of Stroke and Cerebrovascular Diseases. 23(10). 2533–2539. 11 indexed citations
20.
Hradec, J, et al.. (2011). How are statins used in the Czech Republic? STEP survey - results. Cor et Vasa. 53(10). 527–534. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Orion Breakdown of academic impact, for papers by Rohan Pathansali Breakdown of academic impact, for papers by Sylvia Metz‐Schimmerl Breakdown of academic impact, for papers by Judith Frayne Breakdown of academic impact, for papers by Robert G. Hart Breakdown of academic impact, for papers by Ewa Straburzyńska‐Migaj Breakdown of academic impact, for papers by Mojca Stegnar Breakdown of academic impact, for papers by Prahlad Ho Breakdown of academic impact, for papers by Jun Young Chang Breakdown of academic impact, for papers by G. Y. H. Lip
Rankless by CCL
2026